Study at a glance
How does vitamin D get inside cells?
Cells must take in vitamin D before they can activate or break it down. Most vitamin D compounds in the blood are attached to a carrier called vitamin D-binding protein. Some cells use surface proteins called megalin and cubilin to take in these attached compounds. Cells can also get vitamin D compounds that are not attached to the carrier.
How do the kidneys recover vitamin D?
Kidney cells recover vitamin D attached to its carrier from filtered fluid. This prevents vitamin D from being lost in urine and supplies material for activation. In one experiment, blocking this process reduced uptake to about 8.2% of the untreated comparison. In an animal model lacking megalin, blood 25-hydroxyvitamin D fell by about 80%. These results show the importance of this recovery system under the tested conditions.
Do all tissues take in vitamin D in the same way?
Some breast, muscle and stem-cell experiments also linked uptake through surface proteins to vitamin D processing or cell responses. However, uptake differed between cell types and stages of development. Muscle and fat-cell models did not follow the same pattern. The presence of megalin in the parathyroid glands has not been adequately tested as a vitamin D entry route.
Can a blood test show how much vitamin D reaches cells?
Experiments without the carrier protein show that getting vitamin D compounds that are not attached to it remains important for cells. No single entry route has been proven for every tissue. Studies of kidney disease have produced different findings. They also show changes that may partly make up for reduced uptake. A total blood vitamin D result cannot, by itself, show how much reaches the inside of every cell.
Read the full article below ↓Vitamin D metabolism inside a cell begins with substrate access. Khan and colleagues review why this step differs across tissues: most circulating 25-hydroxyvitamin D [25(OH)D] is bound to vitamin D-binding protein (DBP), yet cells do not all use the same mechanism to obtain it. Renal proximal tubular cells have a specialised megalin/cubilin endocytic system, while many other tissues remain compatible with greater dependence on free or bioavailable metabolite.
Why renal uptake matters
In the kidney, filtered DBP-bound vitamin D is recovered by megalin-dependent endocytosis rather than being lost in urine. Receptor-associated protein (RAP), an inhibitor of megalin-mediated uptake, reduced renal DBP uptake in a key experiment to about 8.2% of untreated control. Megalin deficiency also caused a roughly 80% fall in plasma 25(OH)D in the classic work reviewed, accompanied by severe skeletal consequences.
This is metabolically important because proximal tubular cells contain CYP27B1. Recovered 25(OH)D can therefore become intracellular substrate for conversion to 1,25-dihydroxyvitamin D [1,25(OH)2D]. Uptake is part of the activation system, not merely a transport detail.
Extrarenal uptake is functional but heterogeneous
Functional receptor-mediated uptake has been demonstrated outside the kidney. Mammary-cell DBP uptake was temperature dependent and RAP sensitive. Differentiated myotubes accumulated labelled 25(OH)D at roughly two: to three-fold higher levels than myoblasts, and RAP reduced myotube uptake by 66% over 16 hours. Human mesenchymal stem-cell work also linked lower megalin activity to reduced local 1,25(OH)2D biosynthesis and weaker precursor-dependent osteoblastogenic responses.
These examples do not establish a universal extrarenal pathway. Adipocyte differentiation showed a different pattern, and parathyroid megalin has calcium-sensing evidence but has not been adequately tested as a vitamin D uptake mechanism.
The essential qualification
DBP-null models show that free-metabolite access remains biologically relevant. The defensible model therefore contains both receptor-mediated uptake and free or bioavailable entry, with their relative importance determined by tissue, receptor expression, differentiation state and disease context.
Kidney disease further illustrates the limits of simple conclusions. Several CKD and diabetic-nephropathy models show lower megalin expression and increased urinary loss of DBP and vitamin D metabolites, but findings are not completely consistent across species and studies. The source supports tissue-specific substrate handling and compensatory responses, not one universal cellular entry mechanism.
This substrate-access step sits upstream of Vitamin D Metabolism at the Cellular Level and helps explain why Vitamin D Intracrine Activity can differ between tissues.
Primary source
Khan SS, Petkovich M, Holden RM, Adams MA. Megalin and Vitamin D Metabolism: Implications in Non-Renal Tissues and Kidney Disease. Nutrients. 2022;14(18):3690. Read the full paper.
The Full Evidence Review develops the receptor biology, quantitative experiments and disease-model qualifications in full.
Related reading
Cellular uptake and intracellular handling of vitamin D metabolites: Full Evidence Review
full evidence review of cellular vitamin D metabolite uptake, intracellular handling, megalin-mediated transport and differences between tissues.
Read more →Urinary Vitamin D Binding Protein: A Potential Novel Marker of Renal Interstitial Inflammation and Fibrosis
We investigated the value of urinary vitamin D binding protein excretion (uVDBP) as a tubulointerstitial inflammation and fibrosis marker in adriamycin rats, and tested whether uVDBP parallels renal damage and responds to therapy intensification in humans.
Original paper ↗Read more →Urinary Vitamin D Binding Protein and Kidney Injury Molecule-1 Are Potent Predictors of Acute Kidney Injury After Left Ventricular Assist Device Implantation
This study aimed to predict AKI within 90 days post-LVAD by evaluating urinary levels of vitamin D binding protein (VDBP) and kidney injury molecule-1 (KIM-1).
Original paper ↗Read more →Urinary Vitamin D Binding Protein and KIM-1 Are Potent New Biomarkers of Major Adverse Renal Events in Patients Undergoing Coronary Angiography
The purpose of our study was to explore the potential role of urinary VDBP as a biomarker of an acute renal damage.
Original paper ↗Read more →Vitamin D Binding Protein Is Not Involved in Vitamin D Deficiency in Patients with Chronic Kidney Disease
Objective.
Original paper ↗Read more →Vitamin D Receptor and Vitamin D Binding Protein Gene Polymorphisms Are Associated with Renal Allograft Outcome
Vitamin D deficiency has adverse effects on renal allograft outcomes, and polymorphisms of genes encoding vitamin D-binding protein (VDBP) and vitamin D receptor (VDR) are defined to play a role in these conditions.
Original paper ↗Read more →Changes in Skeletal Muscle Troponin T and Vitamin D Binding Protein (DBP) Concentrations in the Blood of Male Amateur Athletes Participating in a Marathon and 100 km Adventure Race
The study included marathon (MR) participants and 100 km adventure race (AR) participants, who were examined before and after the race.
Original paper ↗Read more →Vitamin D-binding protein controls T cell responses to vitamin D
In vitro studies have shown that the active form of vitamin D3, 1α,25-dihydroxyvitamin D3 (1,25(OH)2D3), can regulate differentiation of CD4+ T cells by inhibiting Th1 and Th17 cell differentiation and promoting Th2 and Treg cell differentiation.
Original paper ↗Read more →25-Hydroxyvitamin D and Vitamin D Binding Protein Levels in Patients With Primary Hyperparathyroidism Before and After Parathyroidectomy
To evaluate vitamin D binding protein and free 25-hydroxyvitamin D [25(OH)D] levels in healthy controls compared to primary hyperparathyroidism (PHPT) patients, and to examine PHPT before and after surgery.
Original paper ↗Read more →Changes in circulating 25-hydroxyvitamin D according to vitamin D binding protein genotypes after vitamin D3 or D2 supplementation
We aimed to investigate the changes of total 25(OH)D, 25(OH)D3 and 25(OH)D2 in a Thai cohort, according to type of vitamin D supplement (vitamin D3 or D2) and DBP genotype, after receiving vitamin D3 or D2 for 3 months.
Original paper ↗Read more →Genetic associations with 25-hydroxyvitamin D deficiency in HIV-1-infected youth: fine-mapping for the GC/DBP gene that encodes the vitamin D-binding protein
Serum 25-hydroxyvitamin D [25(OH)D] is often deficient (.
Original paper ↗Read more →Genetic variant in vitamin D-binding protein is associated with metabolic syndrome and lower 25-hydroxyvitamin D levels in polycystic ovary syndrome: A cross-sectional study
All participants were genotyped for polymorphisms rs2282679, rs4588, and rs7041.
Original paper ↗Read more →Maternal and Neonatal Vitamin D Binding Protein Polymorphisms and 25-Hydroxyvitamin D Cutoffs as Determinants of Neonatal Birth Anthropometry
Our aim was to assess the combined effect of maternal and neonatal VDBP polymorphism heterogeneity in conjunction with different maternal and neonatal 25(OH)D cutoffs on the neonatal anthropometric profile at birth.
Original paper ↗Read more →The GC2 haplotype of the vitamin D binding protein is a risk factor for a low plasma 25-hydroxyvitamin D concentration in a Han Chinese population
Compared with VDI, VDS, or both, VDD showed higher plasma concentrations of fasting blood glucose, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and triglycerides in males (P 0.05).
Original paper ↗Read more →The Role of Vitamin D Binding Protein, Total and Free 25-Hydroxyvitamin D in Diabetes
Vitamin D is important for bone health, but may also have extra-skeletal effects.
Original paper ↗Read more →Vitamin D-Binding Protein, Bioavailable, and Free 25(OH)D, and Mortality: A Systematic Review and Meta-Analysis
Introduction: Observational studies reported inverse associations between serum total 25-hydroxyvitamin D (25(OH)D) concentrations and mortality.
Original paper ↗Read more →Vitamin D Binding Protein Genotype Is Associated with Serum 25-Hydroxyvitamin D and PTH Concentrations, as Well as Bone Health in Children and Adolescents in Finland
We examined the role of GC genotypes in S-25(OH)D status and BMD in 231 Finnish children and adolescents aged 7−19 yr.
Original paper ↗Read more →Vitamin D Binding Protein Impact on 25-Hydroxyvitamin D Levels under Different Physiologic and Pathologic Conditions
The aim of this review is to assess DBP concentration in different physiological and pathophysiological conditions.
Original paper ↗Read more →Vitamin D-Binding Protein Polymorphisms, 25-Hydroxyvitamin D, Sunshine and Multiple Sclerosis
Blacks have different dominant polymorphisms in the vitamin D-binding protein (DBP) gene that result in higher bioavailable vitamin D than whites.
Original paper ↗Read more →Assessment of Serum 25-Hydroxyvitamin D and Its Association in Type 2 Diabetes Mellitus Elderly Patients with Kidney Disease: A Retrospective Cross Sectional Study
The overall aim of this study is to determine the prevalence of vitamin D deficiency and its association with diabetic nephropathy in elderly patients with type 2 diabetes mellitus.
Original paper ↗Read more →Association between serum 25-hydroxyvitamin D levels and carotid atherosclerosis in chronic kidney disease patients
Therefore, in this study we have aimed to determine the association between serum 25-hydroxyvitamin D levels and carotid atherosclerosis in the CKD population.
Original paper ↗Read more →Original sources
Read the full paper
Khan SS, Petkovich M, Holden RM, Adams MA.
Publication details
Khan SS, Petkovich M, Holden RM, Adams MA. Megalin and Vitamin D Metabolism: Implications in Non-Renal Tissues and Kidney Disease. Nutrients. 2022;14(18):3690. Read the full paper.